Anaxirone | CAS#77658-97-0 | DNA alkylating agent

MedKoo Cat#: 206057 | Name: Anaxirone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Anaxirone is a synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.

Chemical Structure

Anaxirone

CAS#77658-97-0

Theoretical Analysis

MedKoo Cat#: 206057

Name: Anaxirone

CAS#: 77658-97-0

Chemical Formula: C11H15N3O5

Exact Mass: 269.1012

Molecular Weight: 269.25

Elemental Analysis: C, 49.07; H, 5.62; N, 15.61; O, 29.71

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 250.00	Ready to Ship
5mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Anaxirone; triglycidylurazol; TGU; NSC 332448; NSC-332448; NSC332448; NSC 332844; NSC-332844; NSC332844;

IUPAC/Chemical Name

1,2,4-tris(oxiran-2-ylmethyl)-1,2,4-triazolidine-3,5-dione

InChi Key

ZTXDHEQQZVFGPK-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H15N3O5/c15-10-12(1-7-4-17-7)11(16)14(3-9-6-19-9)13(10)2-8-5-18-8/h7-9H,1-6H2

SMILES Code

O=C(N1CC2OC2)N(CC3OC3)N(CC4OC4)C1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#Y23X03P01

QC Data

View QC data: current batch, Lot#Y23X03P01

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 269.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hilgard P, Peukert M, Pohl J. alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent. Cancer Treat Rev. 1984 Jun;11(2):115-20. doi: 10.1016/0305-7372(84)90003-3. PMID: 6498858. 2: Holdener EE, Clavel M, Sessa C, ten Bokkel Huinink W, Siegenthaler P, Ludwig C, Klepp O, Renard G, Decoster G, Pinedo HM. Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study. Eur J Cancer. 1994;30A(3):394-5. doi: 10.1016/0959-8049(94)90262-3. PMID: 8204365. 3: George M, Scotto V, Carnino F, Dodion P, ten Bokkel Huinink WW, Rotmensz N, Vermorken JB. Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study. Eur J Cancer Clin Oncol. 1987 Jun;23(6):867-9. doi: 10.1016/0277-5379(87)90293-8. PMID: 3653204. 4: Schilcher RB, Young JD, Nowrousian MR, Hoffmann B, Schmidt CG. Reversed-phase high-performance liquid chromatographic determination of anaxirone in biological specimens. J Chromatogr. 1986 May 28;378(1):248-53. doi: 10.1016/s0378-4347(00)80721-5. PMID: 3733978. 5: Fiebig HH, Henss H, Arnold H, von Bültzingslöwen F, Klee M, Queisser W, Peukert M. Phase II trial of anaxirone in advanced non-small cell lung cancer. Cancer Treat Rep. 1987 May;71(5):539-40. PMID: 3567979. 6: Wingen F, Eichmann T, Manegold C, Krempien B. Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat. J Cancer Res Clin Oncol. 1986;111(1):35-41. doi: 10.1007/BF00402773. PMID: 3949849. 7: Hansen SW, Bach F, Hansen HH, Kaplan S, Cavalli F. Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent. Eur J Cancer Clin Oncol. 1985 Mar;21(3):301-5. doi: 10.1016/0277-5379(85)90129-4. PMID: 4007009. 8: Lund B, Hansen F, Hansen M, Hansen HH. Phase II study of 1,2,4-triglycidylurazol (TGU) in previously untreated and treated patients with small cell lung cancer. Eur J Cancer Clin Oncol. 1987 Jul;23(7):1031-3. doi: 10.1016/0277-5379(87)90354-3. PMID: 2822424. 9: Fiebig HH, Schmid JR, Bieser W, Henss H, Lohr GW. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development. Eur J Cancer Clin Oncol. 1987 Jul;23(7):937-48. doi: 10.1016/0277-5379(87)90339-7. PMID: 3665999. 10: Bruntsch U, Dodion P, Ten Bokkel Huinink WW, Hansen HH, Pinedo HM, Hansen M, Renard J, Van Glabbeke M. Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group. Eur J Cancer Clin Oncol. 1986 Jun;22(6):697-9. doi: 10.1016/0277-5379(86)90168-9. PMID: 3743605. 11: Welsh J, Stuart JF, Setanoians A, Blackie RG, Billiaert P, Halbert G, Calman KC. The analysis and animal pharmacokinetics of 1,2,4, triglycidyl urazol using a high-pressure liquid chromatographic technique. Cancer Chemother Pharmacol. 1984;12(3):198-200. doi: 10.1007/BF00256546. PMID: 6705137. 12: Cunningham D, Banham SW, Soukop M. Small cell lung cancer: results of a phase II study of 1,2,4 triglycidylurazol. Cancer Chemother Pharmacol. 1986;17(1):85-6. doi: 10.1007/BF00299872. PMID: 3009043. 13: Beelen DW, Schilcher RB, Ehrlich R, Quabeck K, Schmidt U, Szy D, Grosse- Wilde H, Becher R, Schaefer UW. High-dose 1,2,4-triglycidylurazol given in regimens preparatory to bone marrow transplantation. A preclinical pharmacology study. Cancer Chemother Pharmacol. 1991;27(5):361-6. doi: 10.1007/BF00688858. PMID: 1998996. 14: Nicaise C, Rozencweig M, Crespeigne N, Dodion P, Gerard B, Lambert M, Decoster G, Kenis Y. Phase I study of triglycidylurazol given on a 5-day i.v. schedule. Cancer Treat Rep. 1986 May;70(5):599-603. PMID: 3708609. 15: Rouëssé JG, van Oosterom AT, Capellaere P, Kerbrat P, van Coninge CJ, Thomas D, Benshahar D. Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1413-4. doi: 10.1016/0277-5379(87)90129-5. PMID: 3678328. 16: Wander HE, Berdel WE, Bremer K, Peukert M, Queisser W. 1,2,4-Triglycidylurazol in advanced breast cancer: a trial of the phase II study group of the Association of Medical Oncology, German Cancer Society. Cancer Treat Rep. 1987 Jan;71(1):93-4. PMID: 3791274. 17: Queisser W, Wander HE, Possinger K, Fiebig HH, Heim ME, Peukert M. Phase-II studies of 1,2,4-triglycidylurazol (TGU) in solid tumors. Phase-II Study Group of the Association of Medical Oncology of the German Cancer Society. Onkologie. 1986 Oct;9(5):283-4. doi: 10.1159/000216031. Erratum in: Onkologie 1987 Feb;10(1):10. PMID: 3543780. 18: Wagner H, Possinger K, Bremer K, Donhujsen-Ant R, Peukert M, Queisser W. Phase II trial of 1,2,4-triglycidylurazol in patients with metastasized renal cell carcinoma. Cancer Treat Rep. 1987 Feb;71(2):209-10. PMID: 3802118. 19: Cunningham D, Soukop M, Stuart JF, Setanoians A, Gilchrist NL, Forrest GJ, Kaye SB. A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488). Eur J Cancer Clin Oncol. 1986 Nov;22(11):1325-9. doi: 10.1016/0277-5379(86)90140-9. PMID: 3830214. 20: Friedl P, Berger MR, Rozycki-Gerlach W, Schlag P, Schmähl D. Anticancer drugs: studies on experimental liver infusion and additional systemic detoxification. Cancer Treat Rev. 1987 Dec;14(3-4):247-55. doi: 10.1016/0305-7372(87)90014-4. PMID: 2449961.